Faculty of Medicine, Sudan University of Science and Technology, Sudan
Short Communication
The Clinical and Metabolic Impact of GLP-1 Receptor Agonists
Author(s): Fatima Osman Abdelrahman*
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a
cornerstone in the treatment of type 2 diabetes mellitus (T2DM), offering
potent glycemic control, weight reduction, and cardiovascular benefits.
These agents mimic endogenous GLP-1, enhancing insulin secretion,
inhibiting glucagon release, and slowing gastric emptying. Recent studies
have expanded their potential use beyond diabetes, including obesity
and non-alcoholic fatty liver disease (NAFLD). This article reviews the
pharmacological profile, mechanisms of action, clinical efficacy, and
emerging applications of GLP-1 RAs. Results from clinical trials, such
as SUSTAIN, LEADER, and STEP, have underscored their role in reducing
cardiovascular risks and improving metabolic outcomes. The review
also discusses the future prospects of dual- and tri-agonists and the
implications of combining GLP-1 RAs with o.. View More»
